Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rizatriptan Benzoate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : IntelGenx
Deal Size : Undisclosed
Deal Type : Acquisition
Gensco Pharma Acquires Global Rights and IP for RizaFilm and RizaPort
Details : Through the acquisition, Gensco is advancing its strategic initiatives by bringing innovative migraine treatment solutions. It is currently approved by the FDA and EMA for the treatment of migraine.
Product Name : RizaFilm
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 13, 2025
Lead Product(s) : Rizatriptan Benzoate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : IntelGenx
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Rizatriptan Benzoate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gensco® Pharma Announces RizaFilm Commercialization Update in the United States
Details : Rizafilm (rizatriptan) binds with high affinity to human cloned 5-HT1B/1D receptors. It has received FDA approval for the Treatment of acute migraine. It is approved in EU under the name rizaport.
Product Name : Rizafilm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 26, 2023
Lead Product(s) : Rizatriptan Benzoate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable